James P Allison

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy
    A van Elsas
    Howard Hughes Medical Institute and Cancer Research Lab, University of California, Berkeley, CA 94720, USA
    J Exp Med 194:481-9. 2001
  2. pmc Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells
    P ng Loke
    Howard Hughes Medical Institute, University of California, Berkeley, Berkeley, CA, USA
    Arthritis Res Ther 6:208-14. 2004
  3. pmc TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo
    Rachel A Gottschalk
    Department of Immunology, Howard Hughes Medical Institute, New York, NY 10021, USA
    J Exp Med 207:1701-11. 2010
  4. pmc Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 206:1717-25. 2009
  5. pmc Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors
    Michael A Curran
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:7747-55. 2009
  6. pmc B7x: a widely expressed B7 family member that inhibits T cell activation
    Xingxing Zang
    Howard Hughes Medical Institute, Department of Molecular and Cell Biology, Cancer Research Laboratory, University of California, Berkeley, CA 94720, USA
    Proc Natl Acad Sci U S A 100:10388-92. 2003
  7. ncbi request reprint CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism
    John J Engelhardt
    Division of Immunology, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 177:1052-61. 2006
  8. ncbi request reprint B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse
    Tsvetelina Pentcheva-Hoang
    Department of Molecular and Cell Biology, Cancer Research Laboratory, Howard Hughes Medical Institute, University of California, Berkeley, 94720, USA
    Immunity 21:401-13. 2004
  9. ncbi request reprint The B7 family and cancer therapy: costimulation and coinhibition
    Xingxing Zang
    Howard Hughes Medical Institute, Immunology Program, Ludwig Center of Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:5271-9. 2007
  10. pmc CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
    Brian Kavanagh
    Department of Microbiology and Immunology, Division of Hematology Oncology, University of California, San Francisco, CA 94143, USA
    Blood 112:1175-83. 2008

Collaborators

Detail Information

Publications38

  1. pmc Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy
    A van Elsas
    Howard Hughes Medical Institute and Cancer Research Lab, University of California, Berkeley, CA 94720, USA
    J Exp Med 194:481-9. 2001
    ..Our data demonstrate that therapeutic autoreactive CD8(+) T cell responses can effectively be generated in tumor-bearing mice and stresses the value of studying tumor immunity in a therapeutic rather than a prophylactic setting...
  2. pmc Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells
    P ng Loke
    Howard Hughes Medical Institute, University of California, Berkeley, Berkeley, CA, USA
    Arthritis Res Ther 6:208-14. 2004
    ..The different varieties of regulatory T cells could regulate both naive T cell activation and effector function through costimulatory receptor/ligands...
  3. pmc TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo
    Rachel A Gottschalk
    Department of Immunology, Howard Hughes Medical Institute, New York, NY 10021, USA
    J Exp Med 207:1701-11. 2010
    ..However, in the persistence of induced Foxp3(+) T cells, TCR ligand potency and density are noninterchangeable factors that influence the route to peripheral tolerance...
  4. pmc Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 206:1717-25. 2009
    ....
  5. pmc Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors
    Michael A Curran
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:7747-55. 2009
    ..Engineering Flt3L to be constitutively secreted and attaching an IgG2a tail yielded a B16 vaccine that, when combined with CTLA-4 blockade, prevented the outgrowth of significantly more 5-day implanted B16-BL6 tumors than did Gvax...
  6. pmc B7x: a widely expressed B7 family member that inhibits T cell activation
    Xingxing Zang
    Howard Hughes Medical Institute, Department of Molecular and Cell Biology, Cancer Research Laboratory, University of California, Berkeley, CA 94720, USA
    Proc Natl Acad Sci U S A 100:10388-92. 2003
    ..These studies identify a costimulatory pathway that may have a unique function in downregulation of tissue-specific autoimmunity and antitumor responses...
  7. ncbi request reprint CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism
    John J Engelhardt
    Division of Immunology, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 177:1052-61. 2006
    ..Our data confirm the activity of CTLA-4 as a negative regulator of T cell activation and that its action may be by multiple mechanisms...
  8. ncbi request reprint B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse
    Tsvetelina Pentcheva-Hoang
    Department of Molecular and Cell Biology, Cancer Research Laboratory, Howard Hughes Medical Institute, University of California, Berkeley, 94720, USA
    Immunity 21:401-13. 2004
    ....
  9. ncbi request reprint The B7 family and cancer therapy: costimulation and coinhibition
    Xingxing Zang
    Howard Hughes Medical Institute, Immunology Program, Ludwig Center of Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:5271-9. 2007
    ..Therefore, the manipulation of these pathways is crucial for developing effective tumor immunotherapy. Translation of our basic knowledge of costimulation and coinhibition into early clinical trials has shown considerable promise...
  10. pmc CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
    Brian Kavanagh
    Department of Microbiology and Immunology, Division of Hematology Oncology, University of California, San Francisco, CA 94143, USA
    Blood 112:1175-83. 2008
    ..Our results also suggest that CTLA4 may inhibit Treg proliferation similar to its role on effector T cells. This study is registered at http://www.clinicaltrials.gov/ct2/show/NCT00064129, registry number NCT00064129...
  11. pmc SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
    Marcella Fassò
    Departments of Urology and Medicine, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 105:3509-14. 2008
    ..Our findings demonstrate that our in vivo CTLA-4 blockade-based T cell expression cloning can identify immunogenic cancer antigens with potential relevance for human immunotherapy...
  12. pmc Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses
    Rachel A Gottschalk
    Department of Immunology, Howard Hughes Medical Institute, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 109:881-6. 2012
    ..These observations suggest that models of TCR ligand discrimination must account for disparate sensitivity of downstream responses to specific influences of pMHC potency...
  13. pmc CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
    ....
  14. ncbi request reprint A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors
    Xingxing Zang
    Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genomics 88:841-5. 2006
    ..The p85 unit of PI3K is the only signaling molecule identified so far that interacts with ICOS. This system may be of great help in dissecting the mechanisms of T cell costimulation and could be applied to other receptors...
  15. pmc Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
    Sergio A Quezada
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 207:637-50. 2010
    ....
  16. pmc Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity
    Joyce Wei
    Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Exp Med 208:1683-94. 2011
    ..Data from these two autoimmune models provide evidence that B7x expression in the periphery acts as an immune checkpoint to prevent tissue-specific autoimmunity...
  17. pmc PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
    Michael A Curran
    Department of Immunology, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 107:4275-80. 2010
    ....
  18. doi request reprint Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
    Tsvetelina Pentcheva-Hoang
    Department of Immunology, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Immunol Rev 229:67-87. 2009
    ..The application of findings from basic research has provided insight into the manipulation of these pathways in the clinic and offers promising strategies for the treatment of disease...
  19. doi request reprint Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)
    Tyler R Simpson
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Opin Immunol 22:326-32. 2010
    ..e., bacterial, worm, and viral infections). This multiplicity of roles positions ICOS at the center of attention for immunotherapy where manipulation of this pathway could lead to novel approaches in the treatment of human diseases...
  20. doi request reprint Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes
    Peter A Savage
    Department of Immunology, Howard Hughes Medical Institute, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10021, USA
    Science 319:215-20. 2008
    ..Thus, the repertoire of antigens recognized by tumor-infiltrating T cells is broader than previously thought and includes peptides derived from ubiquitous self antigens that are normally sequestered from immune detection...
  21. doi request reprint Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand
    Emily Corse
    Program in Immunology, Howard Hughes Medical Institute, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 190:526-30. 2013
    ..The CD28 ligand-specific transgenic mice will facilitate evaluation of CD8(+) T cell function in liver disease pathologies found in AIH...
  22. ncbi request reprint CTLA-4: new insights into its biological function and use in tumor immunotherapy
    Jackson G Egen
    Howard Hughes Medical Institute, Department of Molecular and Cell Biology, Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA
    Nat Immunol 3:611-8. 2002
    ..We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer...
  23. pmc Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas
    Xingxing Zang
    Howard Hughes Medical Institute, Immunology Program, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 23:1104-12. 2010
    ..B7-H3 expression in tumor vasculature may be a reflection of tumor aggressiveness and has diagnostic and immunotherapeutic implications in ovarian carcinomas...
  24. ncbi request reprint Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative
    Karl S Peggs
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, 1275 York Avenue, New York, NY 10021, USA
    Cancer Cell 12:192-9. 2007
    ..We argue for combinatorial strategies with agents that target tumor cells to release these antigens together with innovative therapies that enhance immunological responses by interfering with inhibitory checkpoints...
  25. ncbi request reprint BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
    Norihiko Watanabe
    Department of Pathology and Immunology, Howard Hughes Medical Institute, Washington University School of Medicine, Box 8118, 660 South Euclid Avenue, St Louis, Missouri 63110, USA
    Nat Immunol 4:670-9. 2003
    ..B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1)...
  26. ncbi request reprint Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells
    Lauren I Richie Ehrlich
    Department of Microbiology and Immunology and the Cancer Research Institute, University of California, San Francisco, CA 94143, USA
    J Immunol 174:1922-31. 2005
    ..It is, therefore, likely that NKG2D acts as a costimulatory molecule only under restricted conditions or requires additional cofactors...
  27. ncbi request reprint Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Immunol 18:206-13. 2006
    ..Finding ways to dissociate antitumor activity from adverse immune events should enable actualization of their therapeutic potential in the coming years...
  28. doi request reprint Cutting edge: CTLA-4 on effector T cells inhibits in trans
    Emily Corse
    Department of Immunology, Howard Hughes Medical Institute, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 189:1123-7. 2012
    ..Thus, cell-extrinsic inhibition of T cell responses by CTLA-4 is not limited to Tregs but is also a function of effector T cells...
  29. ncbi request reprint Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection
    P ng Loke
    Tropical Disease Research Unit, University of California, San Francisco, CA 94143, USA
    J Immunol 179:3926-36. 2007
    ..However, analogous to classical activation by microbial pathogens, Th2 cells are required for maintenance and full activation during the ongoing response to metazoan parasites...
  30. pmc Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability
    Tsvetelina Pentcheva-Hoang
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 104:17765-70. 2007
    ..PD-1 and CD28 have similar kinetics of synaptic accumulation, suggesting that the process involves T cell receptor-triggered cytoskeletal reorganization followed by ligand binding...
  31. doi request reprint Strength of TCR-peptide/MHC interactions and in vivo T cell responses
    Emily Corse
    Department of Immunology, Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
    J Immunol 186:5039-45. 2011
    ....
  32. pmc Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
    Sergio A Quezada
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Immunol Rev 241:104-18. 2011
    ..Finally, we also discuss work associated to the manipulation of the immune response to tumors and its impact on the infiltration, accumulation, and function of tumor-reactive lymphocytes within the tumor microenvironment...
  33. pmc Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance
    Virginia A Pedicord
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 108:266-71. 2011
    ..These results indicate that transient blockade of CTLA-4 enhances memory CD8(+) T-cell responses and support the possible use of CTLA-4-blocking antibodies during vaccination to augment memory formation and maintenance...
  34. pmc B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
    Xingxing Zang
    Howard Hughes Medical Institute, Immunology Program and Ludwig Center for Cancer Immunotherapy, and Departments of Surgery and Urology, Pathology, and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 104:19458-63. 2007
    ..Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer...
  35. pmc To be or not to be B7
    Xingxing Zang
    Immunology Program, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 116:2590-3. 2006
    ..These findings raise interesting questions regarding the physiological roles and mechanisms of action of this molecule. Identification of dual functions of this molecule provides an additional level of complexity in T cell costimulation...
  36. doi request reprint Expression of Helios in peripherally induced Foxp3+ regulatory T cells
    Rachel A Gottschalk
    Department of Immunology, Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
    J Immunol 188:976-80. 2012
    ..Thus, Helios expression in iTreg may reflect the context of stimulation during Foxp3 induction. In summary, the robust Helios expression we observe in iTreg precludes its use as a marker of thymic Treg...
  37. pmc PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
    P ng Loke
    Howard Hughes Medical Institute, University of California, Berkeley, CA 94720, USA
    Proc Natl Acad Sci U S A 100:5336-41. 2003
    ..These results suggest that PD-L1 and PD-L2 might have different functions in regulating type 1 and type 2 responses...
  38. ncbi request reprint Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength
    Jackson G Egen
    Howard Hughes Medical Institute, Department of Molecular and Cell Biology, Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA
    Immunity 16:23-35. 2002
    ..This may represent a novel feedback control mechanism in which a stimulatory signal regulates the recruitment of an inhibitory receptor to a functionally relevant site on the cell surface...